PURPOSE: To report the outcomes of enhancement after small incision lenticule extraction (SMILE) using the VisuMax CIRCLE option (Carl Zeiss Meditec AG, Jena, Germany), which converts the SMILE cap into a femtosecond LASIK flap for secondary excimer laser application. METHODS: Of 2,065 SMILE procedures, 22 eyes (1.1%) re-treated with CIRCLE with a follow-up of 3 months were included in the analysis. SMILE was performed in the usual manner. For re-treatment, the CIRCLE procedure was performed with pattern D flap creation on the VisuMax system and subsequent excimer laser ablation with a Zeiss MEL 90 laser (Carl Zeiss Meditec) with plano target in all cases. RESULTS: Spherical equivalent was -5.56 ± 2.22 diopters (D) before SMILE and -0.51 ± 1.08 D before CIRCLE. CIRCLE enhancement was performed after a mean of 10.0 ± 7.9 months, allowed for safe flap lifting in all eyes, and resulted in a final manifest refraction spherical equivalent of 0.18 ± 0.31 D at 3 months (P < .008). The number of eyes within 0.50 and 1.00 D from target refraction increased from 31.8% to 90.9% and from 77.3% to 100%, respectively. Mean uncorrected distance visual acuity (UDVA) had already improved from 0.37 ± 0.16 to 0.08 ± 0.16 logMAR at 1 week (P < .0001), resulting in 0.03 ± 0.07 logMAR at 3 months (P < .0001). All eyes gained at least one line of UDVA. Corrected distance visual acuity (CDVA) remained unchanged at all time points (before vs after CIRCLE, P = .40). Two eyes (9.1 %) lost one line of CDVA; no eye lost two or more lines. The safety and efficacy indices were 1.03 and 0.97 at 3 months. CONCLUSIONS: The CIRCLE procedure represents an effective re-treatment option after SMILE. Compared to surface ablation re-treatment after SMILE, CIRCLE seems to offer advantages in respect to speed of visual recovery, safety, and predictability, but at the price of flap creation. [J Refract Surg. 2018;34(5):304-309.]. Copyright 2018, SLACK Incorporated.
PURPOSE: To report the outcomes of enhancement after small incision lenticule extraction (SMILE) using the VisuMax CIRCLE option (Carl Zeiss Meditec AG, Jena, Germany), which converts the SMILE cap into a femtosecond LASIK flap for secondary excimer laser application. METHODS: Of 2,065 SMILE procedures, 22 eyes (1.1%) re-treated with CIRCLE with a follow-up of 3 months were included in the analysis. SMILE was performed in the usual manner. For re-treatment, the CIRCLE procedure was performed with pattern D flap creation on the VisuMax system and subsequent excimer laser ablation with a Zeiss MEL 90 laser (Carl Zeiss Meditec) with plano target in all cases. RESULTS: Spherical equivalent was -5.56 ± 2.22 diopters (D) before SMILE and -0.51 ± 1.08 D before CIRCLE. CIRCLE enhancement was performed after a mean of 10.0 ± 7.9 months, allowed for safe flap lifting in all eyes, and resulted in a final manifest refraction spherical equivalent of 0.18 ± 0.31 D at 3 months (P < .008). The number of eyes within 0.50 and 1.00 D from target refraction increased from 31.8% to 90.9% and from 77.3% to 100%, respectively. Mean uncorrected distance visual acuity (UDVA) had already improved from 0.37 ± 0.16 to 0.08 ± 0.16 logMAR at 1 week (P < .0001), resulting in 0.03 ± 0.07 logMAR at 3 months (P < .0001). All eyes gained at least one line of UDVA. Corrected distance visual acuity (CDVA) remained unchanged at all time points (before vs after CIRCLE, P = .40). Two eyes (9.1 %) lost one line of CDVA; no eye lost two or more lines. The safety and efficacy indices were 1.03 and 0.97 at 3 months. CONCLUSIONS: The CIRCLE procedure represents an effective re-treatment option after SMILE. Compared to surface ablation re-treatment after SMILE, CIRCLE seems to offer advantages in respect to speed of visual recovery, safety, and predictability, but at the price of flap creation. [J Refract Surg. 2018;34(5):304-309.]. Copyright 2018, SLACK Incorporated.
Authors: Marcus Ang; Damien Gatinel; Dan Z Reinstein; Erik Mertens; Jorge L Alió Del Barrio; Jorge L Alió Journal: Eye (Lond) Date: 2020-07-24 Impact factor: 3.775
Authors: Julian Langer; Siegfried Priglinger; Elisabeth M Messmer; Martin Dirisamer; Mehdi Shajari; Wolfgang J Mayer Journal: Am J Ophthalmol Case Rep Date: 2020-05-05
Authors: Majid Moshirfar; Mark T Parsons; Nicholas A Chartrand; Chap-Kay Lau; Seth Stapley; Nour Bundogji; Yasmyne C Ronquillo; Phillip C Hoopes Journal: Clin Ophthalmol Date: 2022-09-12